FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117536083> ?p ?o ?g. }

• W2117536083 endingPage "29112" @default.
• W2117536083 startingPage "29107" @default.
• W2117536083 abstract "Expression of the proto-oncogene c-myb is necessary for proliferation of vascular smooth muscle cells. We have developed synthetic hammerhead ribozymes that recognize and cleave c-myb RNA, thereby inhibiting cell proliferation. Herein, we describe a method for the selection of hammerhead ribozyme cleavage sites and optimization of chemical modifications that maximize cell efficacy. In vitro assays were used to determine the relative accessibility of the ribozyme target sites for binding and cleavage. Several ribozymes thus identified showed efficacy in inhibiting smooth muscle cell proliferation relative to catalytically inactive controls. A combination of modifications including several phosphorothioate linkages at the 5′-end of the ribozyme and an extensively modified catalytic core resulted in substantially increased cell efficacy. A variety of different 2′-modifications at positions U4 and U7 that confer nuclease resistance gave comparable levels of cell efficacy. The lengths of the ribozyme binding arms were varied; optimal cell efficacy was observed with relatively short sequences (13-15 total nucleotides). These synthetic ribozymes have potential as therapeutics for hyperproliferative disorders such as restenosis and cancer. The chemical motifs that give optimal ribozyme activity in smooth muscle cell assays may be applicable to other cell types and other molecular targets. Expression of the proto-oncogene c-myb is necessary for proliferation of vascular smooth muscle cells. We have developed synthetic hammerhead ribozymes that recognize and cleave c-myb RNA, thereby inhibiting cell proliferation. Herein, we describe a method for the selection of hammerhead ribozyme cleavage sites and optimization of chemical modifications that maximize cell efficacy. In vitro assays were used to determine the relative accessibility of the ribozyme target sites for binding and cleavage. Several ribozymes thus identified showed efficacy in inhibiting smooth muscle cell proliferation relative to catalytically inactive controls. A combination of modifications including several phosphorothioate linkages at the 5′-end of the ribozyme and an extensively modified catalytic core resulted in substantially increased cell efficacy. A variety of different 2′-modifications at positions U4 and U7 that confer nuclease resistance gave comparable levels of cell efficacy. The lengths of the ribozyme binding arms were varied; optimal cell efficacy was observed with relatively short sequences (13-15 total nucleotides). These synthetic ribozymes have potential as therapeutics for hyperproliferative disorders such as restenosis and cancer. The chemical motifs that give optimal ribozyme activity in smooth muscle cell assays may be applicable to other cell types and other molecular targets." @default.
• W2117536083 created "2016-06-24" @default.
• W2117536083 creator A5003413433 @default.
• W2117536083 creator A5009999227 @default.
• W2117536083 creator A5012086806 @default.
• W2117536083 creator A5016208432 @default.
• W2117536083 creator A5028009061 @default.
• W2117536083 creator A5028413988 @default.
• W2117536083 creator A5032290596 @default.
• W2117536083 creator A5043658020 @default.
• W2117536083 creator A5044519430 @default.
• W2117536083 creator A5047423018 @default.
• W2117536083 creator A5050477708 @default.
• W2117536083 creator A5062416702 @default.
• W2117536083 creator A5077218395 @default.
• W2117536083 creator A5088101752 @default.
• W2117536083 creator A5089719674 @default.
• W2117536083 date "1996-11-01" @default.
• W2117536083 modified "2023-10-03" @default.
• W2117536083 title "Optimizing the Cell Efficacy of Synthetic Ribozymes" @default.
• W2117536083 cites W1498473683 @default.
• W2117536083 cites W1517316308 @default.
• W2117536083 cites W1522946066 @default.
• W2117536083 cites W1534283916 @default.
• W2117536083 cites W1977029770 @default.
• W2117536083 cites W1990579613 @default.
• W2117536083 cites W2001870404 @default.
• W2117536083 cites W2005359764 @default.
• W2117536083 cites W2018127394 @default.
• W2117536083 cites W2025064593 @default.
• W2117536083 cites W2025116940 @default.
• W2117536083 cites W2034487226 @default.
• W2117536083 cites W2047426600 @default.
• W2117536083 cites W2064824702 @default.
• W2117536083 cites W2078861261 @default.
• W2117536083 cites W2091128862 @default.
• W2117536083 cites W2092975717 @default.
• W2117536083 cites W2133245471 @default.
• W2117536083 cites W2187213934 @default.
• W2117536083 cites W2295634113 @default.
• W2117536083 cites W2336122316 @default.
• W2117536083 cites W2418206398 @default.
• W2117536083 cites W4230164139 @default.
• W2117536083 cites W4238545455 @default.
• W2117536083 cites W4243831105 @default.
• W2117536083 cites W4251116209 @default.
• W2117536083 doi "https://doi.org/10.1074/jbc.271.46.29107" @default.
• W2117536083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8910566" @default.
• W2117536083 hasPublicationYear "1996" @default.
• W2117536083 type Work @default.
• W2117536083 sameAs 2117536083 @default.
• W2117536083 citedByCount "70" @default.
• W2117536083 countsByYear W21175360832012 @default.
• W2117536083 countsByYear W21175360832014 @default.
• W2117536083 countsByYear W21175360832016 @default.
• W2117536083 countsByYear W21175360832021 @default.
• W2117536083 crossrefType "journal-article" @default.
• W2117536083 hasAuthorship W2117536083A5003413433 @default.
• W2117536083 hasAuthorship W2117536083A5009999227 @default.
• W2117536083 hasAuthorship W2117536083A5012086806 @default.
• W2117536083 hasAuthorship W2117536083A5016208432 @default.
• W2117536083 hasAuthorship W2117536083A5028009061 @default.
• W2117536083 hasAuthorship W2117536083A5028413988 @default.
• W2117536083 hasAuthorship W2117536083A5032290596 @default.
• W2117536083 hasAuthorship W2117536083A5043658020 @default.
• W2117536083 hasAuthorship W2117536083A5044519430 @default.
• W2117536083 hasAuthorship W2117536083A5047423018 @default.
• W2117536083 hasAuthorship W2117536083A5050477708 @default.
• W2117536083 hasAuthorship W2117536083A5062416702 @default.
• W2117536083 hasAuthorship W2117536083A5077218395 @default.
• W2117536083 hasAuthorship W2117536083A5088101752 @default.
• W2117536083 hasAuthorship W2117536083A5089719674 @default.
• W2117536083 hasConcept C104317684 @default.
• W2117536083 hasConcept C1491633281 @default.
• W2117536083 hasConcept C150194340 @default.
• W2117536083 hasConcept C151730666 @default.
• W2117536083 hasConcept C153911025 @default.
• W2117536083 hasConcept C175156509 @default.
• W2117536083 hasConcept C185592680 @default.
• W2117536083 hasConcept C2779792011 @default.
• W2117536083 hasConcept C43369102 @default.
• W2117536083 hasConcept C55493867 @default.
• W2117536083 hasConcept C62112901 @default.
• W2117536083 hasConcept C62794011 @default.
• W2117536083 hasConcept C67705224 @default.
• W2117536083 hasConcept C76346623 @default.
• W2117536083 hasConcept C86803240 @default.
• W2117536083 hasConcept C95444343 @default.
• W2117536083 hasConceptScore W2117536083C104317684 @default.
• W2117536083 hasConceptScore W2117536083C1491633281 @default.
• W2117536083 hasConceptScore W2117536083C150194340 @default.
• W2117536083 hasConceptScore W2117536083C151730666 @default.
• W2117536083 hasConceptScore W2117536083C153911025 @default.
• W2117536083 hasConceptScore W2117536083C175156509 @default.
• W2117536083 hasConceptScore W2117536083C185592680 @default.
• W2117536083 hasConceptScore W2117536083C2779792011 @default.
• W2117536083 hasConceptScore W2117536083C43369102 @default.
• W2117536083 hasConceptScore W2117536083C55493867 @default.

• next